Artwork

BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!

Insights from AAPS PharmSci 360 Live with Mark Arnold

29:49
 
साझा करें
 

Manage episode 447991301 series 3593861
BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.


Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis


Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/


How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/


Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/


Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /


Image Credits

  • ​AAPS
  continue reading

28 एपिसोडस

Artwork
iconसाझा करें
 
Manage episode 447991301 series 3593861
BioTalk Unzipped द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BioTalk Unzipped या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.


Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis


Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/


How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/


Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/


Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /


Image Credits

  • ​AAPS
  continue reading

28 एपिसोडस

सभी एपिसोड

×
 
Loading …

प्लेयर एफएम में आपका स्वागत है!

प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।

 

त्वरित संदर्भ मार्गदर्शिका